for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

83.13USD

Change

-2.68(-3.12%)

Volume

3,166,076

Today's Range

82.09

 - 

85.31

52 Week Range

65.26

 - 

92.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Merck Says Lynparza Reduced Risk Of Death By 31% VS Enzalutamide Or Abiraterone For Men With Brca1/2

Sept 20 (Reuters) - Merck & Co Inc <MRK.N>::LYNPARZA REDUCED RISK OF DEATH BY 31% VERSUS. ENZALUTAMIDE OR ABIRATERONE FOR MEN WITH BRCA1/2 OR ATM-MUTATED METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PROGRESSED FOLLOWING ENZALUTAMIDE OR ABIRATERONE IN PHASE 3 PROFOUND TRIAL.MERCK -ASTRAZENECA & CO EXPLORING ADDITIONAL TRIALS IN METASTATIC PROSTATE CANCER INCLUDING ONGOING PHASE 3 PROPEL TRIAL, FIRST DATA EXPECTED IN 2021.

Merck Presents New Data For Three Investigational Medicines At ESMO Virtual Congress 2020

Sept 20 (Reuters) - Merck & Co Inc <MRK.N>::MERCK PRESENTS PROMISING NEW DATA FOR THREE INVESTIGATIONAL MEDICINES FROM DIVERSE AND EXPANSIVE ONCOLOGY PIPELINE AT ESMO VIRTUAL CONGRESS 2020.INITIATE PHASE 3 STUDY OF VIBOSTOLIMAB IN NON-SMALL CELL LUNG CANCER IN FIRST HALF OF 2021.VIBOSTOLIMAB AS MONOTHERAPY OR IN COMBINATION WITH KEYTRUDA HAD A MANAGEABLE SAFETY PROFILE.

Merck And Eisai Present First-Time Data From Two Studies Evaluating Keytruda Plus Lenvima In Seven Different Tumor Types At ESMO

Sept 20 (Reuters) - Merck & Co Inc <MRK.N>::MERCK AND EISAI PRESENT FIRST-TIME DATA FROM TWO STUDIES EVALUATING KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA® (LENVATINIB) IN SEVEN DIFFERENT TUMOR TYPES AT ESMO VIRTUAL CONGRESS 2020.MERCK & CO INC - FINDINGS FROM PHASE 2 LEAP-004 TRIAL SHOWING ORR OF 21.4% IN PATIENTS WITH UNRESECTABLE OR ADVANCED MELANOMA.

Merck's Keytruda Reduced Risk Of Distant Metastasis Or Death By 40% Versus Placebo

Sept 19 (Reuters) - Merck & Co Inc <MRK.N>::MERCK & CO -KEYTRUDA REDUCED RISK OF DISTANT METASTASIS OR DEATH BY 40% VERSUS PLACEBO AS ADJUVANT TREATMENT IN RESECTED, HIGH-RISK STAGE III MELANOMA.MERCK IS ADVANCING A BROAD CLINICAL PROGRAM EVALUATING KEYTRUDA FOR THE EARLY TREATMENT OF CANCER.

Merck & Co Inc Says Lynparza Improved Median Progression-Free Survival To Over 4.5 Years Vs 13.8 Months With Placebo

Sept 18 (Reuters) - Merck & Co Inc <MRK.N>::LYNPARZA® (OLAPARIB) IMPROVED MEDIAN PROGRESSION-FREE SURVIVAL TO OVER FOUR AND A HALF YEARS COMPARED TO 13.8 MONTHS WITH PLACEBO FOR PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER.MERCK & CO INC - FIVE-YEAR FOLLOW-UP DATA FROM PHASE 3 SOLO-1 TRIAL SHOWED LYNPARZA REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 67%.MERCK & CO INC - AT FIVE YEARS, 48.3% OF PATIENTS TREATED WITH LYNPARZA REMAINED FREE FROM DISEASE PROGRESSION VERSUS. 20.5% ON PLACEBO.MERCK & CO INC - SAFETY PROFILE OF LYNPARZA WAS CONSISTENT WITH PREVIOUS OBSERVATIONS IN SOLO-1..MERCK & CO INC - TWELVE PERCENT OF PATIENTS ON LYNPARZA DISCONTINUED TREATMENT DUE TO AN ADVERSE REACTION.

BRENZYS® (Etanercept Injection) Now Indicated For The Treatment Of Plaque Psoriasis, Psoriatic Arthritis And Juvenile Idiopathic Arthritis

Sept 15 (Reuters) - Merck & Co Inc <MRK.N>::BRENZYS® (ETANERCEPT INJECTION) NOW INDICATED FOR THE TREATMENT OF PLAQUE PSORIASIS, PSORIATIC ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS.MERCK & CO INC - HEALTH CANADA HAS APPROVED BRENZYS , A TNF-INHIBITOR, FOR FOUR NEW INDICATIONS.

Seattle Genetics And Merck Announce Two Strategic Oncology Collaborations

Sept 14 (Reuters) - Merck & Co Inc <MRK.N>::SEATTLE GENETICS AND MERCK ANNOUNCE TWO STRATEGIC ONCOLOGY COLLABORATIONS.SEATTLE GENETICS INC - MERCK TO ACQUIRE $1 BILLION EQUITY STAKE IN SEATTLE GENETICS COMMON STOCK.SEATTLE GENETICS INC - COMPANIES TO CO-DEVELOP AND CO-COMMERCIALIZE SEATTLE GENETICS' ANTIBODY-DRUG CONJUGATE LADIRATUZUMAB VEDOTIN GLOBALLY.SEATTLE GENETICS INC - UNDER TERMS OF AGREEMENT, SEATTLE GENETICS WILL RECEIVE A $600 MILLION UPFRONT PAYMENT.SEATTLE GENETICS INC - SEPARATELY HAS GRANTED MERCK AN EXCLUSIVE LICENSE TO COMMERCIALIZE TUKYSA(®) (TUCATINIB).SEATTLE GENETICS INC - SEATTLE GENETICS IS ELIGIBLE FOR PROGRESS-DEPENDENT MILESTONE PAYMENTS OF UP TO $2.6 BILLION FOR LADIRATUZUMAB VEDOTIN.SEATTLE GENETICS - GRANTED MERCK LICENSE TO COMMERCIALIZE TUKYSA IN ASIA, MIDDLE EAST & LATIN AMERICA & OTHER REGIONS OUTSIDE OF U.S., CANADA & EUROPE.SEATTLE GENETICS INC - MERCK WILL MAKE A $1.0 BILLION EQUITY INVESTMENT IN 5.0 MILLION SHARES OF SEATTLE GENETICS COMMON STOCK AT A PRICE OF $200 PER SHARE.SEATTLE GENETICS INC - WILL RECEIVE $125 MILLION FROM MERCK AS UPFRONT PAYMENT AND ELIGIBLE FOR PROGRESS-DEPENDENT MILESTONES OF UP TO $65 MILLION FOR TUKYSA.SEATTLE GENETICS INC - FINANCIAL IMPACT OF THESE COLLABORATIONS IS NOT INCLUDED IN SEATTLE GENETICS' 2020 GUIDANCE.SEATTLE GENETICS INC - WOULD RECEIVE TIERED ROYALTIES ON SALES OF TUKYSA IN MERCK'S TERRITORY.SEATTLE GENETICS - UNDER LADIRATUZUMAB VEDOTIN COLLABORATION, CO IS ELIGIBLE TO RECEIVE UP TO $4.2 BILLION.

Merck Announces Positive Topline Results From Two Phase 3 Adult Studies Evaluating V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial

Sept 9 (Reuters) - Merck & Co Inc <MRK.N>::MERCK ANNOUNCES POSITIVE TOPLINE RESULTS FROM TWO PHASE 3 ADULT STUDIES EVALUATING V114, MERCK’S INVESTIGATIONAL 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, INCLUDING PIVOTAL TRIAL.MERCK & CO INC - APPLICATION FOR V114 LICENSURE IN ADULTS TO BE SUBMITTED BY YEAR-END.MERCK & CO INC - IN BOTH STUDIES, V114 WAS GENERALLY WELL TOLERATED.MERCK & CO INC - TWO PHASE 3 STUDIES EVALUATING V114 MET THEIR PRIMARY IMMUNOGENICITY OBJECTIVES.MERCK & CO INC - PNEU-AGE STUDY ALSO MET KEY SECONDARY IMMUNOGENICITY OBJECTIVE.MERCK & CO - IN BOTH STUDIES, V114 HAD A SAFETY PROFILE COMPARABLE TO PCV13 AND CONSISTENT WITH THAT OBSERVED FOR V114 IN PREVIOUSLY REPORTED STUDIES.

Bayer Says Phase 4 Study Met Its Main Goal In PAH Patients Who Transitioned To Adempas

Sept 7 (Reuters) - Bayer AG <BAYGn.DE>::BAYER PHASE IV STUDY MET ITS PRIMARY ENDPOINT IN PAH PATIENTS WHO HAD TRANSITIONED TO ADEMPAS (RIOCIGUAT) AFTER INSUFFICIENT RESPONSE TO PDE5 INHIBITORS.BAYER - OUTCOMES FROM RANDOMIZED, CONTROLLED, OPEN-LABEL REPLACE STUDY INCLUDED RESULTS FROM 226 PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION.BAYER - MOST COMMON ADVERSE EVENTS INSTUDY WERE GENERALLY CONSISTENT WITH THOSE SEEN IN PIVOTAL PATENT STUDY.

Highlight Therapeutics Says Second Phase II Oncology Collaboration With Merck

Sept 2 (Reuters) - HIGHLIGHT THERAPEUTICS: :HIGHLIGHT THERAPTCS. - SECOND PHASE II ONCOLOGY COLLABORATION WITH MERCK.HIGHLIGHT THERAPEUTICS - FIRST PATIENT DOSED IN PHASE IIA STUDY IN LIVER METASTASIS.HIGHLIGHT THERAPEUTICS- ENTERED INTO SECOND PHASE II TRIAL COLLABORATION WITH A SUBSIDIARY OF MERCK & CO., INC..HIGHLIGHT THERAPEUTICS- COLLABORATION WILL FOCUS ON PHASE II EVALUATION OF COMBINATION OF BO-112, HIGHLIGHT'S LEAD PROGRAM, AND KEYTRUDA®.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up